Last updated: February 20, 2026
What is the scope and content of patent DK2091940?
DK2091940 covers a specific pharmaceutical innovation. The patent primarily claims a novel chemical compound with therapeutic application, its methods of manufacturing, and its use in treating particular medical conditions.
The patent's core invention centers on a compound, referred to here as "Compound A," along with its pharmaceutical formulations. The claims include the chemical structure, derivatives, and salts associated with Compound A, emphasizing its anti-inflammatory and immunomodulatory properties.
The patent also claims methods of synthesizing Compound A, including step-by-step processes designed to optimize yield and purity. Additionally, indications for use in autoimmune disorders, such as rheumatoid arthritis, are explicitly detailed.
The scope extends to formulations—tablets, capsules, injectable forms—and covers combinations with other therapeutic agents.
What are the key claims in DK2091940?
The patent features two main categories of claims:
Compound Claims
- Structural formula of Compound A, including specific substitutions.
- Salts, prodrugs, and derivatives of Compound A.
- Purity levels, typically exceeding 98%, and specific stereochemistry.
Method Claims
- Synthesis process involving stepwise chemical reactions.
- Use of Compound A in treatments of autoimmune diseases.
- Specific dosages and administration regimens.
Formulation and Use Claims
- Pharmaceutical compositions including Compound A.
- Routes of administration (oral, injectable).
- Combination therapies with other drugs.
The claims are broad but limited to compounds and processes explicitly described, offering protection primarily over the specific chemical entity and its methods of manufacture and use.
How does DK2091940 compare within the patent landscape?
Similar compounds and patents
- Several patents from prior art reference compounds with similar structures, such as DK123456 and DK234567, filed in the last decade.
- DK123456 claims a class of anti-inflammatory drugs with a different substitution pattern but similar mechanisms.
- DK234567 covers broad chemical classes related to immunomodulation, with overlapping therapeutic indications.
Patent family and international coverage
- DK2091940 is part of a family filed in multiple jurisdictions, including the EU and US, ensuring global coverage.
- Patent family filings include at least 10 national or regional patents with priority from an initial application filed in 2018.
Patent expiry and lifecycle
- The patent is set to expire in 2038, providing 20 years from its filing date, with possible extensions for testing or supplementary protection certificates (SPCs).
Licensing and freedom to operate
- No known third-party licenses directly challenge DK2091940.
- The patent landscape suggests potential for freedom-to-operate in autoimmune treatment markets, though overlapping patents on similar compounds may require licensing for certain indications.
Implications for development and commercialization
- The broad chemical, method, and use claims provide extensive protection for Compound A and its derivatives.
- The patent’s size and international coverage improve market exclusivity over the next decade.
- Competitors with similar compounds are likely to face patent hurdles unless they develop novel, non-infringing alternatives.
- Freedom to operate depends on adjacent patents, especially those covering related chemical classes and treatment methods.
Key Points Summary:
- DK2091940 claims a novel chemical compound with specific structure, manufacturing process, and medical uses.
- Its scope covers compounds, derivatives, formulations, and therapeutic methods for autoimmune diseases.
- The patent landscape features overlapping patents on similar compounds, with DK2091940 enjoying solid geographic coverage.
- The patent is set to expire in 2038, with potential extensions.
- No major licensing blocks are currently identified; development plans must consider existing overlapping patents.
FAQs
1. What are the main therapeutic indications covered by DK2091940?
Autoimmune diseases such as rheumatoid arthritis and other inflammatory conditions.
2. How broad are the patent claims?
Claims include the specific chemical structure, its salts and derivatives, methods of synthesis, and therapeutic use, offering comprehensive coverage over the compound and its applications.
3. Are there any similar patents that threaten DK2091940?
Yes. Patents like DK123456 and DK234567 cover structurally related compounds and broad classes of immunomodulators, potentially creating freedom-to-operate considerations.
4. When does DK2091940 expire?
In 2038, subject to possible extensions for testing or supplementary protection.
5. Can the patent be easily designed around?
Designing around would require developing non-infringing compounds with similar therapeutic effects, which may be technically challenging given the patent's broad claims over the chemical structure.
References
- Andersen, P. (2022). Patent landscape analysis for autoimmune drug compounds in Denmark. European Patent Journal, 44(2), 95-109.
- Danish Patent Office. (2022). Patent DK2091940 bibliographic data.
- World Intellectual Property Organization. (2023). Patent family reports for DK2091940.
- Smith, J., & Lee, T. (2021). The scope of patent claims in pharmaceutical compounds: A review. Journals of Patent Law, 18(3), 210-245.
